{"id":800859,"date":"2022-06-15T19:00:07","date_gmt":"2022-06-15T17:00:07","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/"},"modified":"2023-07-11T10:37:31","modified_gmt":"2023-07-11T08:37:31","slug":"clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/","title":{"rendered":"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022"},"content":{"rendered":"CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled \u2018Therapeutic vaccination with CLB-3000 in a mouse model of chronic Hepatitis B induces anti-HBs responses associated with functional cure\u2019 was accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2022, taking place in London, UK June 22 - 26, 2022.\n\n\n\n\u201cAs we continue to progress our therapeutic vaccine candidate, CLB-3000, toward first in human trials, we are excited to share our preclinical data with the Hepatitis B community,\u201d said Aileen Rubio, PhD., C<div class=\"leaky_paywall_message_wrap\"><div id=\"leaky_paywall_message\"><a href=\"https:\/\/bebeez.it\/abbonati\/\">Abbonati<\/a> o <a href=\"https:\/\/bebeez.it\/mio-account\/\">Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>CONCORD, Mass.&#8211;(BUSINESS WIRE)&#8211;ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled \u2018Therapeutic vaccination with CLB-3000 in a mouse model of chronic Hepatitis B induces anti-HBs responses associated with functional cure\u2019 was accepted for poster presentation at the European Association for [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-800859","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 - BeBeez\" \/>\n<meta property=\"og:description\" content=\"CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled \u2018Therapeutic vaccination with CLB-3000 in a mouse model of chronic Hepatitis B induces anti-HBs responses associated with functional cure\u2019 was accepted for poster presentation at the European Association for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-15T17:00:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-11T08:37:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"olomaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"olomaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/\"},\"author\":{\"name\":\"olomaster\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\"},\"headline\":\"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022\",\"datePublished\":\"2022-06-15T17:00:07+00:00\",\"dateModified\":\"2023-07-11T08:37:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/\"},\"wordCount\":449,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/\",\"name\":\"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-06-15T17:00:07+00:00\",\"dateModified\":\"2023-07-11T08:37:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518\",\"name\":\"olomaster\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g\",\"caption\":\"olomaster\"},\"url\":\"https:\/\/bebeez.it\/en\/author\/olomaster\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/","og_locale":"en_US","og_type":"article","og_title":"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 - BeBeez","og_description":"CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that its abstract entitled \u2018Therapeutic vaccination with CLB-3000 in a mouse model of chronic Hepatitis B induces anti-HBs responses associated with functional cure\u2019 was accepted for poster presentation at the European Association for [&hellip;]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/","og_site_name":"BeBeez","article_published_time":"2022-06-15T17:00:07+00:00","article_modified_time":"2023-07-11T08:37:31+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"author":"olomaster","twitter_card":"summary_large_image","twitter_misc":{"Written by":"olomaster","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/"},"author":{"name":"olomaster","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518"},"headline":"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022","datePublished":"2022-06-15T17:00:07+00:00","dateModified":"2023-07-11T08:37:31+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/"},"wordCount":449,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/","name":"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022 - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-06-15T17:00:07+00:00","dateModified":"2023-07-11T08:37:31+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/clearb-therapeutics-announces-acceptance-of-abstract-highlighting-pre-clinical-chronic-hepatitis-b-data-as-a-poster-presentation-at-easl-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"ClearB Therapeutics Announces Acceptance of Abstract Highlighting Pre-Clinical Chronic Hepatitis B Data as a Poster Presentation at EASL 2022"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/f3523ef027b0af56aa28725439cc9518","name":"olomaster","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f27d32333d7dec7da2843c6d51349029304daff2c6c3fb07164f8de234678661?s=96&d=mm&r=g","caption":"olomaster"},"url":"https:\/\/bebeez.it\/en\/author\/olomaster\/"}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/800859","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=800859"}],"version-history":[{"count":1,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/800859\/revisions"}],"predecessor-version":[{"id":892177,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/800859\/revisions\/892177"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=800859"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=800859"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=800859"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=800859"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=800859"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}